Skip to content

Evaluation Study for the Programme DiaNe for People With Diabetic Nephropathy

A Prospective Controlled Randomized Multicenter Trial to Evaluate the Effect of a Structurized Multifactorial Behavior Modifying Consultation and Support Programme DiaNe for People With Diabetic Nephropathy

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00782847
Acronym
DiaNe
Enrollment
125
Registered
2008-10-31
Start date
2004-07-31
Completion date
2007-01-31
Last updated
2008-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Nephropathy

Keywords

diabetes mellitus, diabetic nephropathy, hypertension

Brief summary

This study is designated to evaluate the effect of a patients' educational program called DiaNe® for consultation and support people with diabetic kidney disease in an early stage. The aim of the study is to examine if the program is suitable to stop deterioration of kidney function and to maintain or improve glycemic control. The consultation and support program DiaNe® substantially contributes to a better understanding of the affected clients for this complex clinical picture, allows them for specific interventions and creates the rationale for an active therapeutic relationship.

Detailed description

According to statistics diabetes mellitus is considered to be the leading cause for end stage renal disease in Germany, approximately 35% of the patients starting on dialysis are affected by diabetes-induced nephropathy. This can be seen in countries all over the world. This situation has been known for years. To date, neither structured intervention methods nor educational programs have been designed for and targeting those affected, which would consequently allow for structured, multifactorial intervention at an early stage of diabetic nephropathy. Multifactorial interventions, as published in the Steno-2 trial, appear to be highly effective with regard to long-term complications of diabetes. In order to realize this approach for the affected as well as the medical staff caring for patients with diabetes-induced nephropathy we developed DiaNe®, a consultation and support program, which is designed to give detailed information to the affected in order to induce behavioral changes. We were able to show a clinically significant reduction of microalbuminuria within a first monocenter evaluation trial. We wanted to verify this effect by means of a prospective multicenter randomized cohort trial according to GCP-ICH guidelines.

Interventions

BEHAVIORALDiaNe consultation and support program

the DiaNe consultation and support program for clients with diabetic nephropathy consists of 4 sessions at 90-120 minutes conducted every week in a period of 4 weeks

Sponsors

Roche Pharma Deutschland GmbH, Grenzach-Wyhlen, Germany
CollaboratorUNKNOWN
Institute for Medical Outcom Research GmbH, Loerrach, Germany
CollaboratorUNKNOWN
DiaNe HCM GmbH
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* diabetes mellitus * proven diabetic nephropathy by histological/lab findings and/or discretion of nephrologist * ability to understand the German language

Exclusion criteria

* end stage renal disease and/or dialysis * unable or unwilling to follow the protocol * pregnant women * discretion of nephrologist

Design outcomes

Primary

MeasureTime frame
deterioration of kidney function in diabetic nephropathy13 months

Secondary

MeasureTime frame
HbA1c13 months

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026